Database Member Home
RAS Member Home
Biopharmaceutical companies face a rapidly evolving environment, characterized by mounting competition and compliance pressures. This has made it increasingly difficult for organizations to establish and maintain successful relationships with Key opinion leaders (KOLs).
Therefore, organizations must implement innovative practices and tactics for KOL engagement and manage compliance risks while doing so. This Best Practices, LLC video highlights the emerging trends, risks and challenges associated with KOL development and management. It will help Medical Affairs executives stay abreast with the latest trends in the industry and identify the pitfalls in developing and maintaining effective KOL relationships.
A must-have for all pharmaceutical, biotech and medical device manufacturing executives, this Best Practices' R&D Quality Assurance bundle tells you everything you need to know about quality... (ID OPS-95)
Read More »
Best Practices’ Market Research series highlights best practices in market research... (ID SMS-169)
Best Practices’ Pharma Thought Leadership series examines thought leadership in the context of patient advocacy while creating effective relationships and global product launches... (ID SMS-156)
The objective of this benchmarking study is to help biopharma leaders develop competitive launch and pre-launch activity budgets to ensure successful U... (ID PSM-326)
Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs... (ID PSM-229)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area... (ID PSM-267)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the metabolic therapeutic area... (ID PSM-266)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area... (ID PSM-264)